Atypical Ventures — Full Portfolio
5 tracked investments · listed companies and verified rows first
LogicInk develops wearable biochemical sensors that detect environmental and personal health signals—such as UV exposure, air quality, and microbiome changes—to provide real-time wellness feedback.
BiotechConsumerHardwareHealthtechWellness & FitnessSan Francisco, US
Carlos Olguin(Founder & CEO)inHendrik Dietz(Scientific Co-Founder)in
Co-investorsKrillion VenturesVillage GlobalBerkeley CatalystMission Biocapital
Richmond, US
Amy Brachman(Executive Officer)David Vogeleer(Director)Caribou Honig(Director)Steven Shein(Director)Christopher Wake(Director)Charles Merritt(Executive Officer, Director)
Board seatChristopher Wake· per SEC Form D · $7.2M raise · filed Jan 2024
Twosense uses passive biometrics and machine learning for continuous user authentication in enterprise environments, eliminating the need for passwords and physical tokens.
AI & Machine LearningCybersecurityEnterprise SoftwareHealthtechBrooklyn, US
Dawud Gordon(CEO)John Tanios(Executive Officer, Director)
Board seatChristopher Wake· per SEC Form D
Co-investorsBoro CapitalEntrepreneurs Roundtable Accelerator (ERA)Glasswing VenturesOpen Field CapitalFirst InPreface Ventures
Buddy provides embedded insurance technology that allows companies to offer insurance products directly to customers within their digital products or checkout experiences.
AI & Machine LearningInsurTechSaaSWellness & FitnessRichmond, US
Charles Merritt(Co-Founder, CEO)David Vogeleer(Co-Founder, CTO)
Co-investorsTechstars
Parallel Bio develops human immune organoids and computational tools to predict drug efficacy across diverse patient populations, replacing animal testing in drug discovery.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Robert DiFazio(Founder)inJuliana Hilliard(Founder)in
Co-investorsAIX VenturesBreakout VenturesHumba VenturesImmeasurableJulian CapitalMetaplanet+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.